BACKGROUND: Serious congenital heart defects occur as a result of improper atrioventricular septum (AVS) development during embryogenesis. Despite extensive knowledge of the genetic control of AVS development, few genetic lesions have been identified that are responsible for AVS-associated congenital heart defects. METHODS AND RESULTS: We sequenced 32 genes known to be important in AVS development in patients with AVS defects and identified 11 novel coding single-nucleotide polymorphisms that are predicted to impair protein function. We focused on variants identified in the bone morphogenetic protein receptor, ALK2, and subjected 2 identified variants to functional analysis. The coding single-nucleotide polymorphisms R307L and L343P are heterozygous missense substitutions and were each identified in single individuals. The L343P allele had impaired functional activity as measured by in vitro kinase and bone morphogenetic protein-specific transcriptional response assays and dominant-interfering activity in vivo. In vivo analysis of zebrafish embryos injected with ALK2 L343P RNA revealed improper atrioventricular canal formation. CONCLUSIONS: These data identify the dominant-negative allele ALK2 L343P in a patient with AVS defects.
BACKGROUND: Serious congenital heart defects occur as a result of improper atrioventricular septum (AVS) development during embryogenesis. Despite extensive knowledge of the genetic control of AVS development, few genetic lesions have been identified that are responsible for AVS-associated congenital heart defects. METHODS AND RESULTS: We sequenced 32 genes known to be important in AVS development in patients with AVS defects and identified 11 novel coding single-nucleotide polymorphisms that are predicted to impair protein function. We focused on variants identified in the bone morphogenetic protein receptor, ALK2, and subjected 2 identified variants to functional analysis. The coding single-nucleotide polymorphisms R307L and L343P are heterozygous missense substitutions and were each identified in single individuals. The L343P allele had impaired functional activity as measured by in vitro kinase and bone morphogenetic protein-specific transcriptional response assays and dominant-interfering activity in vivo. In vivo analysis of zebrafish embryos injected with ALK2L343P RNA revealed improper atrioventricular canal formation. CONCLUSIONS: These data identify the dominant-negative allele ALK2L343P in a patient with AVS defects.
Authors: Teun van der Bom; A Carla Zomer; Aeilko H Zwinderman; Folkert J Meijboom; Berto J Bouma; Barbara J M Mulder Journal: Nat Rev Cardiol Date: 2010-11-02 Impact factor: 32.419
Authors: Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell Journal: Circulation Date: 2018-11-20 Impact factor: 29.690
Authors: Todd A Townsend; Jamille Y Robinson; Tam How; Daniel M DeLaughter; Gerard C Blobe; Joey V Barnett Journal: Cell Signal Date: 2011-09-14 Impact factor: 4.315
Authors: Annastasia S Hyde; Erin L Farmer; Katherine E Easley; Kristy van Lammeren; Vincent M Christoffels; Joseph J Barycki; Jeroen Bakkers; Melanie A Simpson Journal: J Biol Chem Date: 2012-07-18 Impact factor: 5.157
Authors: Laura E Briggs; Aimee L Phelps; Elizabeth Brown; Jayant Kakarla; Robert H Anderson; Maurice J B van den Hoff; Andy Wessels Journal: Circ Res Date: 2013-04-12 Impact factor: 17.367
Authors: Christine Ackerman; Adam E Locke; Eleanor Feingold; Benjamin Reshey; Karina Espana; Janita Thusberg; Sean Mooney; Lora J H Bean; Kenneth J Dooley; Clifford L Cua; Roger H Reeves; Stephanie L Sherman; Cheryl L Maslen Journal: Am J Hum Genet Date: 2012-10-05 Impact factor: 11.025